"Study Finds No Surgical Infection Risk From TNF Inhibitors" - Ted Bosworth
Patients undergoing surgery with detectable levels of a tumor necrosis factor inhibitor are not at increased risk for postoperative infection, according to one of the largest prospective studies to address this issue. Based on the findings, “preoperative use of a TNF inhibitor should not affect the decision to perform surgery in most IBD patients,” said Benjamin Cohen, MD, MAS, associate professor of medicine and gastroenterology at the Icahn School of Medicine at Mount Sinai. He added, “By using a large prospective cohort, we were able to define, assess and control for a broad array of risks for postoperative infection.”
— Benjamin L. Cohen, MD, MAS, Associate Professor, Medicine, Gastroenterology, Icahn School of Medicine at Mount Sinai
Researchers Identify Potential Target for Treatment Among Patients With Type 2 Diabetes
Aug 04, 2022 View All Press Releases
Mount Sinai Researcher Receives Prestigious International Award
Jul 06, 2022 View All Press Releases
Combination of Chemo and Immunotherapy Is Shown to Work Against Metastatic Bladder Cancer
May 15, 2020 View All Press Releases